151 related articles for article (PubMed ID: 34557315)
1. Prognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma.
Díez-Alonso M; Mendoza-Moreno F; Gómez-Sanz R; Matías-García B; Ovejero-Merino E; Molina R; Soto-Schütte S; San Juan A; Gutierrez-Calvo A
Int J Surg Oncol; 2021; 2021():3946875. PubMed ID: 34557315
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases.
Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Aulicino M; Vaira M; De Franciscis S; D'Acapito F; Carboni F; Milone E; Donini A; Fugazzola P; Faviana P; Sorrentino L; Pizzolato E; Cenzi C; Del Bianco P; Sommariva A
ESMO Open; 2024 Apr; 9(4):102976. PubMed ID: 38613907
[TBL] [Abstract][Full Text] [Related]
3. Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma.
Rose JS; Serna DS; Martin LK; Li X; Weatherby LM; Abdel-Misih S; Zhao W; Bekaii-Saab T
Cancer; 2012 Dec; 118(24):6243-52. PubMed ID: 22674181
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC.
Graf W; Cashin PH; Ghanipour L; Enblad M; Botling J; Terman A; Birgisson H
Ann Surg Oncol; 2020 Jan; 27(1):293-300. PubMed ID: 31571052
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Factors of Survival in Patients with Peritoneal Metastasis from Colorectal Cancer.
Mendoza-Moreno F; Diez-Alonso M; Matías-García B; Ovejero-Merino E; Gómez-Sanz R; Blázquez-Martín A; Quiroga-Valcárcel A; Vera-Mansilla C; Molina R; San-Juan A; Barrena-Blázquez S; Ortega MA; Alvarez-Mon M; Gutiérrez-Calvo A
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013160
[TBL] [Abstract][Full Text] [Related]
6. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.
Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ
J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598
[TBL] [Abstract][Full Text] [Related]
7. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population.
Schirripa M; Nappo F; Cremolini C; Salvatore L; Rossini D; Bensi M; Businello G; Pietrantonio F; Randon G; Fucà G; Boccaccino A; Bergamo F; Lonardi S; Dei Tos AP; Fassan M; Loupakis F
Clin Colorectal Cancer; 2020 Sep; 19(3):219-225. PubMed ID: 32605718
[TBL] [Abstract][Full Text] [Related]
8. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases.
Sakai N; Furukawa K; Takayashiki T; Kuboki S; Takano S; Ohtsuka M
BMC Cancer; 2021 Apr; 21(1):412. PubMed ID: 33858364
[TBL] [Abstract][Full Text] [Related]
10. Metastatic Profile of Colorectal Cancer: Interplay Between Primary Tumor Location and KRAS Status.
Zihui Yong Z; Ching GTH; Ching MTC
J Surg Res; 2020 Feb; 246():325-334. PubMed ID: 30737098
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
[TBL] [Abstract][Full Text] [Related]
12. The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer.
Huang CW; Tsai HL; Chen YT; Huang CM; Ma CJ; Lu CY; Kuo CH; Wu DC; Chai CY; Wang JY
BMC Cancer; 2013 Dec; 13():599. PubMed ID: 24330663
[TBL] [Abstract][Full Text] [Related]
13. KRAS status in patients with colorectal cancer peritoneal carcinomatosis and its impact on outcome.
Gillern SM; Chua TC; Stojadinovic A; Esquivel J
Am J Clin Oncol; 2010 Oct; 33(5):456-60. PubMed ID: 19952717
[TBL] [Abstract][Full Text] [Related]
14. Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.
Sasaki Y; Hamaguchi T; Yamada Y; Takahashi N; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Nagai Y; Taniguchi H; Boku N; Ushijima T; Shimada Y
Asian Pac J Cancer Prev; 2016; 17(2):539-43. PubMed ID: 26925640
[TBL] [Abstract][Full Text] [Related]
15. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis.
Kim HS; Heo JS; Lee J; Lee JY; Lee MY; Lim SH; Lee WY; Kim SH; Park YA; Cho YB; Yun SH; Kim ST; Park JO; Lim HY; Choi YS; Kwon WI; Kim HC; Park YS
BMC Cancer; 2016 Feb; 16():120. PubMed ID: 26887348
[TBL] [Abstract][Full Text] [Related]
16. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
17. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
18. Association of KRAS mutation with tumor deposit status and overall survival of colorectal cancer.
Zhang M; Hu W; Hu K; Lin Y; Feng Z; Yun JP; Gao N; Zhang L
Cancer Causes Control; 2020 Jul; 31(7):683-689. PubMed ID: 32394229
[TBL] [Abstract][Full Text] [Related]
19. Mutation Status and Prognostic Value of KRAS and BRAF in Southeast Iranian Colorectal Cancer Patients: First Report from Southeast of Iran.
Yari A; Samoudi A; Afzali A; Karam ZM; Karimaldini NK; Abadi MFS; Ziasistani M; Zangouey MR; Dabiri S
J Gastrointest Cancer; 2021 Jun; 52(2):557-568. PubMed ID: 32495109
[TBL] [Abstract][Full Text] [Related]
20. Impact of Single-organ Metastasis to the Liver or Lung and Genetic Mutation Status on Prognosis in Stage IV Colorectal Cancer.
Cavallaro P; Bordeianou L; Stafford C; Clark J; Berger D; Cusack J; Kunitake H; Francone T; Ricciardi R
Clin Colorectal Cancer; 2020 Mar; 19(1):e8-e17. PubMed ID: 31899147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
